Table 3.
Cohort | Low Risk Men | High Grade Cancer Among Low Risk Men |
---|---|---|
PSA 10 – 25 ng / mL (n=255) | ||
<7.5% risk threshold | ||
OPKO (N=102) | 22 (22%) | 1 (4.5%) |
UPCA (N=153) | 12 (8%) | 0 (0.0%) |
Total | 34 (13%) | 1 (2.9%) |
<10% risk threshold | ||
OPKO (N=102) | 24 (24%) | 1 (4.2%) |
UPCA (N=153) | 16 (10%) | 0 (0.0%) |
Total | 40 (16%) | 1 (2.5%) |
Positive DRE (n=449) | ||
<7.5% risk threshold | ||
OPKO (N=240) | 61 (25%) | 0 (0.0%) |
UPCA(N=209) | 6 (3%) | 1 (16.7%) |
Total | 67 (15%) | 1 (1.5%) |
<10% risk threshold | ||
OPKO (N=240) | 81 (34%) | 1 (1.2%) |
UPCA (N=209) | 12 (6%) | 1 (8.3%) |
Total | 93 (21%) | 2 (2.2%) |
PSA 10 – 25 ng / mL or positive DRE (n=615) | ||
Total: <7.5% threshold | ||
OPKO (N=321) | 81 (25%) | 1 (1.2%) |
UPCA (N=294) | 17 (6%) | 1 (5.9%) |
Total | 98 (16%) | 2 (2.0%) |
Total: <10% threshold | ||
OPKO (N=321) | 103 (32%) | 2 (1.9%) |
UPCA (N=294) | 26 (9%) | 1 (3.8%) |
Total | 129 (21%) | 3 (2.3%) |